Amnovis Scales Medical Implant Production Using Pure Titanium and Automation

Amnovis marked its fifth anniversary by shipping its 100,000th 3D-printed implant, a milestone announced in a press release datelined Aarschot, Belgium - October 14, 2025, and told TCT Magazine in a March 2, 2026 Additive Insight podcast that it has scaled manufacturing to produce 60,000 implants a year. CEO and co‑founder Ruben Wauthle framed the company’s ambition in the podcast with the line, "We want to redefine the state of the art in additive manufacturing."

Founded in June 2020 by Peter Mercelis and Ruben Wauthle, Amnovis operates from Aarschot and positions itself as a contract manufacturer and engineering company using laser powder bed fusion (L‑PBF) metal 3D‑printing for medical and industrial applications. Wauthle spelled out the company’s culture in the Oct 14, 2025 press materials: "From day one, we wanted Amnovis to be more than just another supplier. We set out to build a company that consistently delivers high-quality parts, communicates transparently, and meets deadlines. Five years later, we’re proud to say we’re doing exactly that."

The product slate is rooted in titanium additive work. Amnovis prints titanium spinal implants and has developed a porous structure made from pure titanium to coat acetabular cups, a capability described in BoneZone and tied to clinical handling advantages. As Dr. Wauthle told BoneZone, "The porous structure can be deformed, meaning surgeons can hammer it into bone or mold it preoperatively to achieve a specific fit," and "It’s a flexible solution that merges the benefits of standardized implant production with personalized surgery." The PR also includes imagery and a scaled replica of the 100,000th shipped implant, courtesy of Promethean Restorative LLC.

On materials development and industrial expansion, Amnovis is running R&D programs to print components with two or more metals via L‑PBF and is scaling a powder modification technology called CuperNova. The company describes CuperNova as "An IP protected powder modification method that enhances the laser absorptivity of copper alloys, improving shelf life and flowability while enabling printing with standard lasers." Amnovis’ PR notes the company is scaling powder modification and pilot manufacturing lines for industrial applications alongside its medical production.

Quality and regulatory posture underpins the scaling story. Amnovis is described in industry profiles as ISO 13485 certified and FDA registered, and company leadership prioritized a digital quality management system from day one, adopting Scilife with Quality Manager Bert Engelen to support fast growth and change management. Amnovis lists media contact Ruben Wauthle at ruben.wauthle@amnovis.com and +32 498 302894 in its press materials.

With a cumulative shipment milestone of 100,000 implants and a stated output of 60,000 implants per year, Amnovis is moving from a medical-first manufacturer toward broader industrial work while advancing multi‑metal L‑PBF and proprietary powder treatments as the next commercialization milestones.